Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2015

View Archived Issues

Prediction of tumor response to anti-PD-1 therapy in metastatic melanoma

Roche begins phase I study of RO-6927005 in solid tumors

Merck KGaA commences phase I trial of MSC-2490484A

First patient dosed in phase Ib trial of SYN-004 for the prevention of C. difficile infection

NephroGenex successfully completes QT study of Pyridorin

Warner Chilcott begins phase III study of sarecycline in acne vulgaris

Phase I study of intravenously administered BMS-986168 begins

GABA-A receptor modulation shows promising results for the treatment of autism spectrum disorders

Treatment ongoing in a phase I/II clinical trial of the antitumor RNAi therapeutic TKM-080301

Knight Therapeutics forms product commercialization partnership with NeurAxon

Preclinical investigation of a small-molecule JAK1/TYK2 inhibitor for psoriasis

MMP-3 may be a sex-specific marker of psychiatric disease

Researchers identify novel PS1 mutation involved in early-onset FAD

Shuttle Pharmaceuticals awarded NIH contract for novel radiation sensitizer in GI cancers

4D Pharma advances development of Blautix

United Therapeutics signs agreement with DEKA for development of Remodulin pump system

FDA approves trial protocol for Aethlon's Hemopurifier in patients infected with Ebola virus

Cempra reports results from phase III trial of solithromycin in bacterial pneumonia

Nav1.7 sodium channel blockers described in Amgen patents

Ferrer patents novel orexin OX2 receptor agonists

University of Texas System reports discovery of allosteric proteasome inhibitors

Antabio prepares and tests NDM-1 inhibitors for beta-lactam-resistant infections

Dual specificity protein kinase TTK inhibitors in early development at Bayer

Bristol-Myers Squibb identifies Factor VIIa inhibitors

Promising data revealed on rindopipemut for the treatment of relapsed glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...